ReviewClinical medicine & research2005
Relaxin: antifibrotic properties and effects in models of disease.
Review in Clinical medicine & research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 90 citations in OpenAlex.
- Obstetric sacroiliac joint injury: a case report and discussion.BMC pregnancy and childbirth · 2026Article
- Therapeutic potential of Relaxin-2 in Heart Failure with preserved Ejection Fraction (HFpEF).bioRxiv : the preprint server for biology · 2026Article
- The dual and multifaceted role of relaxin-2 in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Relaxin treatment stimulates the differentiation of mesenchymal stem cells into osteoblasts.Journal of dental sciences · 2023Article
- Long-Term Outcomes After Epigastric Hernia Repair in Women-A Nationwide Database Study.Journal of abdominal wall surgery : JAWS · 2023Article
- Epithelial to mesenchymal transition in mammary gland tissue fibrosis and insights into drug therapeutics.PeerJ · 2023Article
- Identification of a distal RXFP1 gene enhancer with differential activity in fibrotic lung fibroblasts involving AP-1.PloS one · 2021Article
- The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease.Molecular genetics & genomic medicine · 2020Review
- Pre-clinical Research on Bladder Toxicity After Radiotherapy for Pelvic Cancers: State-of-the Art and Challenges.Frontiers in oncology · 2020Review
- Human Relaxin-2 Fusion Protein Treatment Prevents and Reverses Isoproterenol-Induced Hypertrophy and Fibrosis in Mouse Heart.Journal of the American Heart Association · 2019Article
- Intraarticular injection of relaxin-2 alleviates shoulder arthrofibrosis.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Relaxin-2 therapy reverses radiation-induced fibrosis and restores bladder function in mice.Neurourology and urodynamics · 2018Article
- Umbilical Hernia Repair and Pregnancy: Before, during, after….Frontiers in surgery · 2018Review
- Differences in the renal antifibrotic cGMP/cGKI-dependent signaling of serelaxin, zaprinast, and their combination.Naunyn-Schmiedeberg's archives of pharmacology · 2017Article
- Human relaxin gene expression delivered by bioreducible dendrimer polymer for post-infarct cardiac remodeling in rats.Biomaterials · 2016Article
- Involvement of Cyclic Guanosine Monophosphate-Dependent Protein Kinase I in Renal Antifibrotic Effects of Serelaxin.Frontiers in pharmacology · 2016Article
- Kynurenine increases matrix metalloproteinase-1 and -3 expression in cultured dermal fibroblasts and improves scarring in vivo.The Journal of investigative dermatology · 2014Article
- Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice.Clinical science (London, England : 1979) · 2013Article
- The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.American journal of physiology. Regulatory, integrative and comparative physiology · 2013Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrosis (progressive scarring) is a leading cause of organ failure worldwide and causes loss of organ function when normal tissue is replaced with excess connective tissue. Several organs are prone to this process regardless of etiology. The pleiotropic hormone, relaxin, is emerging as a novel antifibrotic therapy. Relaxin has been shown to limit collagen production and reorganization, while stimulating increased collagen degradation. It not only prevents fibrogenesis, but also reduces established scarring. This review summarizes (1) the levels at which relaxin inhibits collagen production and existing collagen overexpression in induced models of fibrosis, and (2) the collagen-related phenotypes of relaxin- and LGR7-deficient mice. Recent studies on relaxin-deficient mice have established relaxin as an important, naturally occurring regulator of collagen turnover and provide new insights into the therapeutic potential of relaxin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.